These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 10190950)
1. Autologous stem cell transplantation in advanced follicular lymphoma. A single center experience. López R; Martino R; Sureda A; Nomdedéu J; Briones J; Martin-Henao G; García J; Brunet S; Sierra J Haematologica; 1999 Apr; 84(4):350-5. PubMed ID: 10190950 [TBL] [Abstract][Full Text] [Related]
2. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600 [TBL] [Abstract][Full Text] [Related]
3. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350 [TBL] [Abstract][Full Text] [Related]
4. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases]. Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021 [TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144 [TBL] [Abstract][Full Text] [Related]
6. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience. Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E; Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients]. Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547 [TBL] [Abstract][Full Text] [Related]
9. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation. Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284 [TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. González-Barca E; Fernández de Sevilla A; Domingo-Claros A; Romagosa V; Martín-Henao GA; De Sanjose S; Carmona M; Petit J; García J; Grañena A Bone Marrow Transplant; 2000 Nov; 26(10):1051-6. PubMed ID: 11108302 [TBL] [Abstract][Full Text] [Related]
12. [High dose therapy with autologous stem cell transplantation in patients with Hodgkin's lymphoma: long-term follow-up in patients treated in one center]. Trnĕný M; Vacková B; Pytlík R; Cieslar P; Válková V; Gasová Z; Kobylka P; Trnková M; Krejcová H; Klener P Cas Lek Cesk; 2006; 145(1):19-24. PubMed ID: 16468237 [TBL] [Abstract][Full Text] [Related]
13. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission. Papajik T; Raida L; Faber E; Vondrakova J; Prochazka V; Kubova Z; Skoumalova I; Jarosova M; M LK; Paucek B; Myslivecek M; Neoral C; Oral I; Jarkovsky J; Dusek L; Indrak K Neoplasma; 2008; 55(3):215-21. PubMed ID: 18348654 [TBL] [Abstract][Full Text] [Related]
14. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
15. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience. Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD; Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma. Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727 [TBL] [Abstract][Full Text] [Related]
17. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group. Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D; Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400 [TBL] [Abstract][Full Text] [Related]
18. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma. Mahé B; Milpied N; Mellerin MP; Moreau P; Morineau N; Vigier M; Harousseau JL Bone Marrow Transplant; 2003 Mar; 31(6):467-73. PubMed ID: 12665842 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of autologous stem cell transplantation in mantle cell lymphoma: a 3-year follow-up study. Decaudin D; Brousse N; Brice P; Haioun C; Bourhis JH; Morel P; Van Hoof A; Souleau B; Quesnel B; Gisselbrecht C Bone Marrow Transplant; 2000 Feb; 25(3):251-6. PubMed ID: 10673695 [TBL] [Abstract][Full Text] [Related]
20. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit. Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S Breast J; 2006; 12(6):531-5. PubMed ID: 17238982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]